Response of BRCA1-mutated gallbladder cancer to olaparib: A case report

被引：3

作者：

Yuan Xie ^{[1
]}

Yan Jiang ^{[2
]}

Xiao-bo Yang ^{[1
]}

An-qiang Wang ^{[1
]}

Yong-chang Zheng ^{[1
]}

Xue-shuai Wan ^{[1
]}

Xin-ting sang ^{[1
]}

Kai Wang ^{[3
]}

Da-Dong Zhang ^{[2
]}

Jia-Jia Xu ^{[2
]}

Fu-gen Li ^{[2
]}

Hai-tao Zhao ^{[1
]}

机构：

[1] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

[2] Institute of Precision Medicine, 3D Medicines Inc 3. Center for Precision Medicine, Zhejiang University International Hospital

来源：

World Journal of Gastroenterology | 2016年 / 46期

关键词：

BRCA; Mutation; Olaparib; Poly ADP-ribose polymerase inhibitor; gallbladder cancer;

D O I：

暂无

中图分类号：

R735.8 [胆囊、胆道肿瘤];

学科分类号：

100214 ;

摘要：

gallbladder cancer(gbc), although considered as a relatively rare malignancy, is the most common neoplasm of the biliary tract system. the late diagnosis and abysmal prognosis present challenges to treatment. the overall 5-year survival rate for metastatic gbc patients is extremely low. BRC A1 and BRCA2 are the breast cancer susceptibility genes and their mutation carriers are at a high risk for cancer development, both in men and women. Olaparib, an oral poly ADP-ribose polymerase inhibitor, has been approved by the Food and Drug Administration and the European commission for the treatment of ovarian cancer with any BRCA1/2 mutations. the first case of BRCA1-mutated gbc patient who responded to olaparib treatment is reported here.

引用

页码：10254 / 10259

页数：6

共 50 条

[41] Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases [J].

Asazuma, Kazuki ;

Shimomura, Akihiko ;

Kawamura, Yukino ;

Taniyama, Tomoko ;

Shimizu, Chikako .

CASE REPORTS IN ONCOLOGY, 2024, 17 (01) :773-778

[42] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer [J].

McCrea, Charles ;

Hettle, Robert ;

Gulati, Poonam ;

Taneja, Ankush ;

Rajora, Preety .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) :1021-1030

[43] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer [J].

Cho, Angela ;

Park, Jeong-Yeol ;

Lee, Shin-Wha ;

Kim, Dae-Yeon ;

Suh, Dae-Shik ;

Kim, Jong-Hyeok ;

Kim, Yong-Man ;

Kim, Young-Tak .

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) :1055-1063

[44] Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study [J].

Bourien, Heloise ;

Lefevre, Leila Bengrine ;

Mouret-Reynier, Marie-Ange ;

Asselain, Bernard ;

Lucas, Brigitte ;

Gavoille, Celine ;

Cornila, Corina ;

Gavoille, Laurene ;

Colomba, Emeline ;

Patsouris, Anne ;

Fabbro, Michel ;

Chakiba, Camille ;

Toussaint, Philippe ;

Simon, Helene ;

Berton, Dominique ;

Garbay, Delphine ;

Tixidre, Claire Garnier ;

Coeffic, David ;

Morvan, Aurelie ;

Collard, Olivier ;

Rouge, Thibault De La Motte .

ANTICANCER RESEARCH, 2023, 43 (02) :653-662

[45] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer [J].

Angela Cho ;

Jeong-Yeol Park ;

Shin-Wha Lee ;

Dae-Yeon Kim ;

Dae-Shik Suh ;

Jong-Hyeok Kim ;

Yong-Man Kim ;

Young-Tak Kim .

Archives of Gynecology and Obstetrics, 2021, 304 :1055-1063

[46] PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports [J].

Collot, Thomas ;

Niogret, Julie ;

Carnet, Marion ;

Chevrier, Sandy ;

Humblin, Etienne ;

Favier, Laure ;

Bengrine-Lefevre, Leila ;

Desmoulins, Isabelle ;

Arnould, Laurent ;

Boidot, Romain .

MOLECULAR MEDICINE REPORTS, 2021, 23 (01) :1-8

[47] First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer [J].

Roy, Somnath ;

Ghosh, Joydeep ;

Ganguly, Sandip ;

Biswas, Bivas ;

Bhaumik, Jaydip .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)

[48] BRCA2-positive lung adenocarcinoma treated with olaparib: A case report [J].

Motohashi, Takumi ;

Isobe, Kazutoshi ;

Yoshizawa, Takahiro ;

Usui, Yusuke ;

Shimizu, Hiroshige ;

Sekiya, Muneyuki ;

Miyoshi, Shion ;

Nakamura, Yasuhiko ;

Urabe, Naohisa ;

Sakamoto, Susumu ;

Homma, Sakae ;

Sadamoto, Sota ;

Tochigi, Naobumi ;

Kishi, Kazuma .

RESPIROLOGY CASE REPORTS, 2024, 12 (03)

[49] Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report [J].

Vornhuelz, Marlies ;

Angelberger, Marianne ;

Sirtl, Simon ;

Philipp, Alexander B. ;

Roessler, Daniel ;

Ondrejkova, Katarina ;

Markwardt, Daniel ;

Heinrich, Kathrin ;

Westphalen, Christoph Benedikt ;

Heinemann, Volker ;

Jung, Andreas ;

Rogowski, Paul ;

Niyazi, Maximilian ;

Kleger, Alexander ;

Mayerle, Julia ;

Beyer, Georg .

ONCOLOGY RESEARCH AND TREATMENT, 2025,

[50] Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers [J].

Labidi-Galy, S. Intidhar ;

Rouge, Thibault de La Motte ;

Derbel, Olfa ;

Wolfer, Anita ;

Kalbacher, Elsa ;

Olivier, Timothee ;

Combes, Jean-Damien ;

Heimgartner-Hu, Ketty ;

Tredan, Olivier ;

Guevara, Hemerson ;

Heudel, Pierre-Etienne ;

Reverdy, Thibaut ;

Bazan, Fernando ;

Heinzelmann-Schwarz, Viola ;

Fehr, Mathias ;

de Castelbajac, Victoire ;

Vaflard, Pauline ;

Crivelli, Louise ;

Bonadona, Valerie ;

Viassolo, Valeria ;

Buisson, Adrien ;

Golmard, Lisa ;

Rodrigues, Manuel ;

Ray-Coquard, Isabelle .

GYNECOLOGIC ONCOLOGY, 2019, 155 (02) :262-269

← 1 2 3 4 5 →